Statin guidelines: Friend or foes?

GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1459–1544.

Murray CJ Vos T Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197–2223.

Barton P Andronis L Briggs A et al. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ 2011; 343: d4044–d4044.

Brugts JJ Yetgin T Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376–b2376.

Taylor F Huffman MD Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816–CD004816.

Cohen JD Brinton EA Ito MK et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6: 208–215.

Pandya A Sy S Cho S et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015; 314: 142–150.

Stone NJ Robinson JG Lichtenstein AH et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889–2934.

National Institute for Health and Care Excellence. Cardiovascular disease: Risk assessment and reduction, including lipid modification. CG181. Clinical Guidelines, London: National Clinical Guideline Centre, 2014.

Anderson TJ Gregoire J Pearson GJ et al. 2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2016; 32: 1263–1282.

Bibbins-Domingo K Grossman DC et al. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 316: 1997–2007.

Piepoli MF Hoes AW Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23: NP1–NP96.

Greenland P Bonow RO . Interpretation and use of another statin guideline. JAMA 2016; 316: 1977–1979.

Schonmann Y, Bleich O, Matalon A, et al. Validation of the 2016 USPSTF recommendations for primary cardiovascular prevention in a large contemporary cohort. Eur J Prev Cardiol. 2018; 25: 870–880.

Mortensen MB Nordestgaard BG . Comparison of five major guidelines for statin use in primary prevention in a contemporary general population. Ann Intern Med 2018; 168: 85–92.

Nayor M Vasan RS . Recent update to the US cholesterol treatment guidelines: a comparison with international guidelines. Circulation 2016; 133: 1795–1806.

Finegold JA Shun-Shin MJ Cole GD et al. Distribution of lifespan gain from primary prevention intervention. Open Heart 2016; 3: e000343–e000343.

Mihaylova B Emberson J et al. Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581–590.

Yusuf S Bosch J Dagenais G et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2021–2031.

Sniderman AD Thanassoulis G Williams K et al. Risk of premature cardiovascular disease vs the number of premature cardiovascular events. JAMA Cardiol 2016; 1: 492–494.